Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.
ChargePoint’s Growth Prospects Buoyed By EV Adoption, Analyst Warns Of Tesla Competition Amid Weak Commercial Deliveries
Needham analyst Chris Pierce reiterated the Buy rating on ChargePoint Holdings, Inc. (NYSE: CHPT)